Date: June 16, 2026
Transaction Details
Zydus Lifesciences Ltd. announced the successful completion of its cash tender offer for Assertio Holdings, Inc. (Nasdaq: ASRT) through its wholly-owned subsidiary Zara Merger Sub Inc. The acquisition was completed at a purchase price of $23.50 per share of common stock of Assertio, without interest, less deduction for any required withholding taxes.
Tender Offer Results
As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on June 15, 2026, 4,286,488 shares of common stock were validly tendered and not withdrawn. This represents approximately 66.32% of the total number of Assertio's issued and outstanding shares of common stock. All tendered shares have been accepted for payment in accordance with the terms of the tender offer.
Merger Completion
The Company intends to complete the acquisition on June 16, 2026 through a merger of Zara Merger Sub Inc. with and into Assertio, with Assertio continuing as the surviving corporation. All shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share, without interest, less deduction for any required withholding taxes.
Post-Acquisition Status
After the completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences Ltd. The common stock of Assertio will no longer be listed or traded on the Nasdaq Global Market.
Company Background
Zydus Lifesciences Ltd. is described as an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D. The company has introduced several innovative, first-in-class products in the market over the last decade, including vaccines, therapeutics, biologicals, and New Chemical Entities.
Contacts
Media Contact: Sujatha Rajesh (Email: sujatha.rajesh@zyduslife.com, Mobile: 9974051180)
Investor Contact: Arvind Bothra (Email: arvind.bothra@zyduslife.com, Mobile: 9833853107)